WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2015121265) STABLE POLYMORPH FORM B OF TAPENTADOL HYDROCHLORIDE
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2015/121265    International Application No.:    PCT/EP2015/052785
Publication Date: 20.08.2015 International Filing Date: 10.02.2015
IPC:
C07C 215/54 (2006.01), A61K 31/135 (2006.01), A61P 13/00 (2006.01)
Applicants: AZAD PHARMACEUTICAL INGREDIENTS AG [CH/CH]; Durachweg 15 CH-8200 Schaffhausen (CH)
Inventors: BOCK, Dominique Anna; (DE).
MAIER, Thomas; (DE).
HAFERKAMP, Sven; (DE).
PORSTMANN, Frank; (CH)
Agent: MICHALSKI HÜTTERMANN & PARTNER PATENTANWÄLTE MBB; Dr. Uwe Albersmeyer Speditionstr. 21 40221 Düsseldorf (DE)
Priority Data:
1402377.4 12.02.2014 GB
Title (EN) STABLE POLYMORPH FORM B OF TAPENTADOL HYDROCHLORIDE
(FR) FORME POLYMORPHE B STABLE DU CHLORHYDRATE DE TAPENTADOL
Abstract: front page image
(EN)The present invention relates to Tapentadol Hydrochloride in the polymorphic crystalline Form B, which is substantially free of polymorphic Form A as well as essentially free of low alkyl carboxylic acids or esters of such acids. Furthermore, the present invention provides a process to produce this polymorphic Form B substantially free of Form A and its preparation and use for pharmaceutical compositions. This process as well as the specific crystalline form is uncommon, improved and industrially advantageous. Furthermore, the invention relates to pharmaceutical compositions and uses thereof.
(FR)La présente invention concerne le chlorhydrate de tapentadol sous la forme polymorphe B cristalline, qui est sensiblement exempt de forme polymorphe A ainsi que sensiblement dépourvu d'acides alkyl carboxylique faibles ou d'esters de ces acides. En outre, la présente invention concerne un procédé pour produire cette forme polymorphe B sensiblement exempte de forme A et sa préparation et son utilisation pour des compositions pharmaceutiques. Ce procédé ainsi que la forme cristalline spécifique, n'est pas commun, est amélioré et industriellement avantageux. En outre, la présente invention concerne des compositions pharmaceutiques et leurs utilisations.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)